Combined prenatal screening of trimester I of pregnancy as a prognostic marker of Great obstetrical syndromes development




combined prenatal screening of the first trimester, ultrasound examination, biochemical markers, great obstetric syndromes


Purpose - to conduct an analysis of the combined prenatal screening of the trimester I of pregnancy in women who had complications from the group of great obstetric syndromes.

Materials and methods. A retrospective statistical analysis of the combined prenatal screening of the trimester I was carried out. Of the 239 pregnant women (Group I - main) who had complications from the group of great obstetric syndromes, according to the data of the pregnancy monitoring exchange cards, combined prenatal screening of the trimester I was carried out in 65.3% of pregnant women, which amounted to 156 pregnant women who were divided into three subgroups: Ia (n=74) pregnant women with severe preeclampsia, Ib (n=40) pregnant women with placental insufficiency, clinically verified fetal growth retardation; Ic (n=42) of pregnant women with spontaneous premature birth in the gestation period of 22-36 weeks. The control group (CG) was 56 practically healthy pregnant women with a healthy reproductive history and an uncomplicated course of this pregnancy. Statistical processing of the research results was carried out using standard Microsoft Excel 5.0 and Statistica 6.0 programs.

Results. In the Group I, the average term of trimester I screening was 12 weeks 3±4 days, in the CG - 12 weeks 1±3 days, the difference in the gestational term of the trimester I combined screening was statistically insignificant. The lowest level of PAPP-A was determined in subgroups Ia and subgroup Ic. In the Group I, the level of PAPP-A was on average 2.16 (1.35-3.24) IU/l and 0.836 (0.571-1.14) MoM, and in CG - 2.62 (1.82-4, 12) MO/l and 1.16 (0.786-1.7) MoM. According to the relative number of patients with a level of PAPP-A <0.5 MoM, no significant differences were found between the Group I and CG, but in subgroup Ib the percent of such patients was the highest, which is significantly more than in CG.  More significant differences were found at the level of PAPP-A <0.3 MoM: in Group I there were 11 (7.05%) patients with a level of PAPP-A <0.3 MoM, in CG - 1 (1.78%). The number of patients with a level of PAPP-A >1.5 MoM, on the contrary, turned out to be the largest in CG - 15 (26.8%) compared to 23 (14.7%) in the Group I and with subgroup Ia - 9 (12.2%). The level of β-hCG in the studied groups was not statistically significant. There was no statistically significant difference in the thickness of the nuchal translucency, but in the Group I this indicator was slightly higher. The largest nuchal translucency value was in subgroup 1b. There were no statistically significant differences in the frequency of the absence of imaging of the nasal bone during ultrasound screening. According to the frequency of detection of reverse blood flow in the ductus venosus, it was not possible to detect statistically significant differences. This sign occurred only in 3 (1.92%) patients of the Group 1 (1 patient in each subgroup) and in 1 (1.78%) patient of CG.

Conclusions. In patients who later developed pregnancy complications belonging to the group of great obstetric syndromes, in the trimester I, a number of prenatal screening indicators differ from those in patients with a physiological course of pregnancy. When conducting a standard set of prenatal diagnostics, the most significant differences were found in the level of PAPP-A (MoM). The results obtained during the analysis of PAPP-A are promising from the point of view of using this parameter as an element of the prognostic model of great obstetric syndromes for the successful course of pregnancy and the birth of a child with a normal body weight.

The research was carried out in accordance with the principles of the Declaration of Helsinki. The research protocol was approved by the Local Ethics Committee of the institution mentioned in the work. Women’s informed consent was obtained for the study.

No conflict of interests was declared by the author.


Bersinger NA, Keller PJ, Naiem A et al. (1987). Pregnancy-specific and pregnancy-associated proteins in threatened abortion. Gynecol Endocrinol. 1 (4): 379-384.; PMid:2459901

Bilagi A. (2017). Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study. Prenatal Diagnosis. 37(7): 705-711.; PMid:28514830

Brizot ML, Carvalho MH, Liao AW et al. (2001). First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Ultrasound Obstet Gynecol. 18 (6): 652-655.; PMid:11844209

Cuckle H. (2001). Time for total shift to first-trimester screening for Down's syndrome. Lancet. 358 (9294): 1658-1659.

De Jong A. (2015). Prenatal screening: current practice, new developments, ethical challenges Bioethics. 29 (1): 1-8.; PMid:25521968

Edwards L. (2018). First and second trimester screening for fetal structural anomalies. Seminars in Fetal and Neonatal Medicine. 23 (2): 102-111.; PMid:29233624

Glants S. (1998). Mediko-biologicheskaya statistika: per. s angl. Moskva: Praktika: 459.

Kaijomaa M. (2016). The risk of adverse pregnancy outcome among pregnancies with extremely low maternal PAPP-A. Prenat Diagn. 36 (12): 1115-1120.; PMid:27750370

Khalil A, Rodgers M, Baschat A et al. (2016). ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. Ultrasound Obstet Gynecol. 47 (2): 247-263.; PMid:26577371

Khalil A, Rodgers M, Baschat A et al. (2017). ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. Ul'trazvukovaya i funkcional'naya diagnostika. 2: 70-103.; PMid:26577371

Krauskopf AL. (2015). Predicting SGA neonates using first-trimester screening: influence of previous pregnancy's birthweight and PAPP-A MoM. The Journal of Maternal-Fetal and Neonatal Medicine. 29 (18): 1-19.; PMid:26551433

Lang TA, Sesik M. (2011). Kak opisyivat statistiku v meditsine. Rukovodstvo dlya avtorov, redaktorov i retsenzentov. Moskva: Prakticheskaya Meditsina: 480.

Markelova AN, Muradyan MM, Pavlenko KI. (2019). Possibility of using biochemical screening parameters to diagnose pregnancy complications. VII Mezhdunarodnaya nauchnaya konferenciya «Aktual'nye problemy medicinskoj nauki i obrazovaniya (APMNO2019)»: sbornik statej. Penza: Izd-vo PGU: 309-313. URL:

Mintser AP. (2010). Statisticheskie metodyi issledovaniya v klinicheskoy meditsine. Prakticheskaya meditsina. 3: 41-45.

Morris RK. (2017). Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenatal Diagnosis. 37 (3): 253-265.; PMid:28012202

Morssink LP, Kornman LH, Hallahan TW et al. (1998). Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn. 18 (2): 147-152.<147::AID-PD231>3.0.CO;2-W

Nicolaides KH. (2011). A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment. Prenat Diagn. 31: 3-6.; PMid:21210474

Poon LC. (2009). First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 53: 812e8.; PMid:19273739

Poulsen HK, Westergaard JG, Teisner B et al. (1987). Measurements of hCG and PAPP-A in uncommon types of ectopic gestation. Eur J Obstet Gynecol Reprod Biol. 26 (1): 33-37.

Quibel T. (2018). What are the real purpose and scope of screening for aneuploidy? Gynecol Obstet Fertil Senol. 46 (2): 124-129.

Richardson WS, Wilson MC, Nishikawa J, Hayward RS. (1995). The well-built clinical question: a key to evidence-based decisions. ACP J Club. 123 (3): A12-13.

Samchuk PM, Azoeva EL, Ischenko AI, Rozalieva YuYu. (2020). Prenatalnyiy skrining kak prediktor gestatsionnyih oslozhneniy. Voprosyi ginekologii, akusherstva i perinatologii. 19 (6): 5-11.

Samchuk PM, Azoeva EL, Oveshnikova TZ. (2020). Platsentarnaya nedostatochnost v gruppe vyisokogo riska po prenatalnomu skriningu. Materialyi 13-go regionalnogo nauchno-obrazovatelnogo foruma i plenuma pravleniya rossiyskogo obschestva akusherov i ginekologov «Mat i Ditya» - 29-30 iyunya 2020 goda. Kazan, M.: 75-76.

Sokol J. (2018). Glycoprotein VI Gene Variants Affect Pregnancy Loss in Patients With Platelet Hyperaggregability. Clin Appl Thromb Hemost. 24 (9): 202-208.; PMid:30278775 PMCid:PMC6714835

Suzumori N. (2018). Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy. Eur J Obstet Gynecol Reprod Biol. 224: 165-169.